Archive for the 'Formulation' Category

Leaving Needles Behind

Erik Greb PharmTech editorHave you ever considered getting a flu shot but quailed at the sight of the needle? Lots of people hate getting injections, but this delivery method is still the predominant technique for administering biological drugs. Rising demand for vaccines and other biologicals is one factor spurring manufacturers to seek alternative delivery methods that could one day rescue the needlephobic. Read more »

Toward Personalized Diabetes Treatment

Maribel Rios PharmTech editorEfforts toward drug formulations that take into account genetic makeup will require a new examination of how disease develops in the body, thereby making it possible to connect biology with the chemical functions of a drug’s active ingredient. Read more »

The Nanoparticle Link in Process Understanding

Maribel Rios PharmTech editorPharmaceutical scientists are still just beginning to understand the working mechanisms of nano-sized particles in drug delivery. For formulators, one of the key challenges has been to design particles that increase bioavailability of the drug to specific targets but still have minimal side effects to the patient. For manufacturers, processing nanomedicines requires having to rethink traditional production operations. How do the unique properties of nano-sized particles affect the means in which they are handled, blended, mixed, coated, lyophilized? Read more »

Fighting Drug Abuse with Drug Delivery

Erik Greb PharmTech editorReports of teenagers’ pharm parties, Rush Limbaugh’s OxyContin addiction, and the questions surrounding Michael Jackson’s death have kept prescription-drug abuse in the public eye. By requiring manufacturers of opioid drugs to create risk evaluation and mitigation strategies, the US Food and Drug Administration is seeking to reduce opportunities for drug abuse while keeping the therapies available to patients who need them. One pharmaceutical company suggests that, in addition to regulatory solutions, drug abuse could be curbed using drug-delivery strategies. Read more »

Boosting Patient Compliance with IT (and Video Games)

Maribel Rios PharmTech editorMy colleague Erik Greb wrote an interesting blog post yesterday about new drug delivery technology reminiscent of childhood games. Games have changed dramatically, but the concept of using them to help educate applies today. Take for example, the problem of patient compliance. A video game called “Re-Mission” (HopeLab) is helping children and teens to “blast away” cancer cells (at least on screen). The point is that it empowers the young patient to take control, which unfortunately is not the case with many adult patients with cancer. Read more »

Collaborative Business Models a Key Focus at ExcipientFest

Patricia Van Arnum PharmTech editor Relationship building and the benefit of deepening collaborative business models between excipient manufacturers and pharmaceutical companies in support of formulation development and manufacturing in a quality-by-design (QbD) paradigm and enhancing supply-chain practices was a key takeaway from ExcipientFest Americas, which was held in San Juan, Puerto Rico, this week. ExcipientFest Americas is operated by the Drug, Chemical and Associated Technologies Association (DCAT). ExcipientFest Americas is an exhibition and educational program that addresses technical considerations in excipient selection and formulation development as well as sourcing and supply-chain issues for excipients. Read more »

Innovators Attempt a Technical Knockout

Erik Greb PharmTech editorWhen faced with determined opponents, sports teams sometimes work the referees to win the game. A victory based on an interpretation of the rules is a victory nonetheless. The team of Warner Chilcott (Rockaway, NJ), Medicis Pharmaceutical (Scottsdale, AZ), Roche (Basel), and Stiefel Laboratories (Coral Gables, FL) recently used this tactic in their competition with generic drugmakers. The companies filed citizen petitions with the US Food and Drug Administration in an attempt to delay the approval of generic versions of their antibiotics. Read more »

Virus Changes Pose New Difficulties

Maribel Rios PharmTech editorIt is inspiring to read news about the advancements being made in the fight against viral infections, including those against influenza and HIV. However, as comments to recent blog posts have reminded me, the struggle to develop antiviral therapies is highly complicated because viruses have the infamous tendency to mutate and adapt in their fight for survival and conquest of healthy cells. A major part of formulating and developing antivirals is trying to get some handle on a virus’s unpredictable nature, how it will change, and how these modified forms will strengthen our understanding of its interworkings. Read more »

Court rules no link between MMR vaccine and autism

Maribel Rios PharmTech editorI remember clearly receiving the warning from my child’s pediatrician regarding claims possibly linking the measles, mumps, and rubella (MMR) vaccine and autism. I also recall my pediatrician, herself a new mother, saying she was going to wait for further evidence before allowing her child to be administered the vaccine. That was eight years ago. Has the question regarding the possible link between the MMR vaccine and autism finally been answered? Read more »

AAPS 2008 Coverage :: Videos from the Show Floor

At this year’s AAPS Annual Meeting and Exposition, Pharmaceutical Technology editors conducted video interviews with industry leaders recorded live at PharmTech’s booth on the exhibit floor. Click on the titles below to watch the vidcasts.

Read more »

« Previous PageNext Page »